ARS Pharmaceuticals Investors Urged to Secure Counsel Before Deadline
News related to:ARS Pharmaceuticals, Inc · 2 min read
Rosen Law Firm, a global investor rights law firm, has reminded investors in ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) of an important deadline as part of a securities class action lawsuit. The law firm is urging investors who purchased ARS Pharmaceuticals securities between March 9, 2026, and June 24, 2026, inclusive, to secure legal counsel before October 5, 2026.
According to the lawsuit, ARS Pharmaceuticals provided investors with misleading information regarding the expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. The company stated with confidence that this coverage would begin on July 1, 2026, and would be in place for the summer and back-to-school allergy seasons. The lawsuit claims that these statements were false and misleading, or that the company concealed material adverse facts that influenced investor decisions.
"The defendants' statements were intended to create an artificial sense of security among investors, leading them to purchase ARS Pharmaceuticals securities at inflated prices," said Phillip Kim, Esq., a partner at Rosen Law Firm. "When the truth emerged, investors suffered significant financial losses."
The lawsuit alleges that the true details of the delayed insurance coverage became public, leading to a drop in the company's stock price. Investors who purchased securities during the class period are now seeking compensation through a class action lawsuit. The Rosen Law Firm represents investors in such cases and aims to secure compensation for those affected by the alleged misrepresentations.
"To join the class action, investors are encouraged to visit https://rosenlegal.com/cases/ars-pharmaceuticals-inc/join or contact Rosen Law Firm directly," Kim added.
The class action lawsuit was filed with the intention of representing all investors who were impacted by the alleged misrepresentations. Investors who wish to serve as lead plaintiff must move the court by the October 5, 2026, deadline to be considered. A lead plaintiff will act on behalf of other class members in directing the litigation.
Rosen Law Firm has a track record of success in handling securities class actions and shareholder derivative litigation. The firm has achieved significant settlements and has represented investors in numerous high-profile cases, including the largest settlement against a Chinese company.
The lawsuit highlights the importance of transparency and accurate financial reporting in the pharmaceutical industry. Investors are advised to stay informed and seek legal counsel to protect their rights.